# Does extracellular vesicle specificity truly exist?

**Authors:** Subhashini Muhandiram, Alireza Fazeli

PMC · DOI: 10.1186/s12964-026-02654-0 · Cell Communication and Signaling : CCS · 2026-01-27

## TL;DR

This review explores whether extracellular vesicles (EVs) can specifically target certain cells and highlights the need for better understanding of their mechanisms and functional relevance.

## Contribution

The paper proposes a refined definition of EV specificity based on functional outcomes rather than mere uptake.

## Key findings

- EV specificity may occur during binding, internalization, or functional response stages.
- Many internalized EVs are degraded without functional impact, challenging assumptions about their relevance.
- The paper emphasizes the need to focus on functional outcomes to define meaningful EV specificity.

## Abstract

Extracellular vesicles (EVs) are nano-sized membranous particles secreted by nearly all cell types that facilitate intercellular communication through the transfer of bioactive cargo. Growing evidence suggests that EVs may exhibit targeting specificity toward particular cells, yet the mechanisms remain poorly understood. In this review, we critically examine the concept of EV target specificity by outlining three potential stages where it may arise: (1) EV binding to the recipient cell membrane, (2) internalization and cargo release and (3) the induction of functional responses within recipient cells. We further explore how EV-intrinsic properties, recipient cell characteristics, and the surrounding microenvironment collectively shape these interactions. A key challenge in the field is the frequent assumption that EV uptake equates to functional relevance. In reality, many internalized EVs are recycled or degraded in lysosomes without eliciting any measurable effect. We therefore propose a refined definition of EV specificity, emphasizing that functional outcomes should serve as the central criterion for establishing meaningful EV specificity. Rather than offering definitive answers, this review highlights unresolved questions and calls for deeper investigation into how EVs select their target cells. Understanding these fundamental principles of EV function is critical for advancing the clinical and therapeutic application of EVs.

## Full-text entities

- **Genes:** CD209 (CD209 molecule) [NCBI Gene 30835] {aka CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1, hDC-SIGN}, RAB27A (RAB27A, member RAS oncogene family) [NCBI Gene 5873] {aka GS2, HsT18676, RAB27, RAM}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, AGFG1 (ArfGAP with FG repeats 1) [NCBI Gene 3267] {aka HRB, RAB, RIP}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, JMJD6 (jumonji domain containing 6, arginine demethylase and lysine hydroxylase) [NCBI Gene 23210] {aka PSR, PTDSR, PTDSR1}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, RAB7B (RAB7B, member RAS oncogene family) [NCBI Gene 338382] {aka RAB7}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, SNAR-E (small NF90 (ILF3) associated RNA E) [NCBI Gene 100170220], TIMD4 (T cell immunoglobulin and mucin domain containing 4) [NCBI Gene 91937] {aka SMUCKLER, TIM4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, MIR210 (microRNA 210) [NCBI Gene 406992] {aka MIRN210, mir-210}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, TSPAN8 (tetraspanin 8) [NCBI Gene 7103] {aka CO-029, TM4SF3}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, TFAP2A (transcription factor AP-2 alpha) [NCBI Gene 7020] {aka AP-2, AP-2alpha, AP2TF, BOFS, TFAP2}, CLTC (clathrin heavy chain) [NCBI Gene 1213] {aka CHC, CHC17, CLH-17, CLTCL2, Hc, MRD56}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MFGE8 (milk fat globule EGF and factor V/VIII domain containing) [NCBI Gene 4240] {aka BA46, EDIL1, HMFG, HsT19888, MFG-E8, MFGM}, SDCBP (syndecan binding protein) [NCBI Gene 6386] {aka MDA-9, MDA9, SDCBP1, ST1, SYCL, TACIP18}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, DNM2 (dynamin 2) [NCBI Gene 1785] {aka CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR150 (microRNA 150) [NCBI Gene 406942] {aka MIRN150, miRNA150, mir-150}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, SMPD2 (sphingomyelin phosphodiesterase 2) [NCBI Gene 6610] {aka ISC1, NSMASE, NSMASE1}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, RAB11A (RAB11A, member RAS oncogene family) [NCBI Gene 8766] {aka YL8}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}
- **Diseases:** inflammation (MESH:D007249), CLL (MESH:D015451), pancreatic adenocarcinoma (MESH:D010190), myeloma (MESH:D009101), Cancer (MESH:D009369), Hypoxic (MESH:D002534), acute kidney injury (MESH:D058186), tumorigenesis (MESH:D063646), neurological disorders (MESH:D009461), Hypoxia (MESH:D000860), metastasis (MESH:D009362), EV (MESH:D004819), breast cancer (MESH:D001943), glioblastoma (MESH:D005909)
- **Chemicals:** mannose (MESH:D008358), acids (MESH:D000143), glycans (MESH:D011134), glycosphingolipids (MESH:D006028), ganglioside GM1 (MESH:D005677), sialic acid (MESH:D019158), Cholesterol (MESH:D002784), ceramide (MESH:D002518), galactose (MESH:D005690), heparan sulfate (MESH:D006497), SM (MESH:D013109), glycosaminoglycan (MESH:D006025), glycerol (MESH:D005990), phosphatidylserine (MESH:D010718), GlcNAc (MESH:D000117), polystyrene (MESH:D011137), Lipids (MESH:D008055), calcium (MESH:D002118), reactive oxygen species (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Human immunodeficiency virus 1 (no rank) [taxon 11676], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** U937 — Homo sapiens (Human), Adult acute monocytic leukemia, Cancer cell line (CVCL_0007), H929 — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_1600), MM.1S — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_8792), U266 — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_0566), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), NTM — Homo sapiens (Human), Transformed cell line (CVCL_5G34), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004), cells — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_M624), C3A — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_1098), COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), Jurkat T — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065), HS-5 — Homo sapiens (Human), Transformed cell line (CVCL_3720), vein — Homo sapiens (Human), Finite cell line (CVCL_3722), MT4 — Homo sapiens (Human), Transformed cell line (CVCL_2632), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), COLO205 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0218), Mino — Homo sapiens (Human), Mantle cell lymphoma, Cancer cell line (CVCL_1872)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12918545/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12918545/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12918545/full.md

---
Source: https://tomesphere.com/paper/PMC12918545